A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC（SHR-1210-AIN457）
Status:
Not yet recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
This is a Phase Ib/IIa, Open-label, Investigator-initiated Trail of SHR-1210 (an Anti-PD-1
Inhibitor) in combination with AIN457 for patients with late stage MSS CRC who failed
second-line and above treatment.
The main purpose of this study is to evaluate the safety, tolerability and RD of SHR-1210
combination with AIN457 as a treatment of MSS CRC.